This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
Lay Description
To investigate the efficacy, safety and tolerability of BI 409306 once daily compared to placebo given for 52 weeks to subjects with attenuated psychosis syndrome.
Category
- Aging and Geriatric
- Genetics
- IRB Number
- 20180639HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- 16 Years - 30 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
Exclusion Criteria
Study Design
Study Contact
Regulatory Point of Contact
Floyd Jones
210-450-3158
jonesfa@uthscsa.edu
Regulatory Point of Contact
Amy Saklad
210-567-8229
saklada@uthscsa.edu
Regulatory Point of Contact
Mary Woolsey
210-567-8049
woolseym@uthscsa.edu